OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press32210.17650/1818-8346-2019-13-4-67-74HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОКRole of KIR typing in donor selection prior to allogeneic hematopoietic stem cell transplantation: literature reviewЦелесообразность проведения KIR-типирования при подборе донора для аллогенной трансплантации гемопоэтических стволовых клеток: обзор литературыhttps://orcid.org/0000-0001-5949-5317ZakharovaV. V.ЗахароваВ. В.
Russian Federation

1 Samory Mashela St., Moscow 117997

Виктория Витальевна Захарова 

117997 Москва, ул. Саморы Машела, 1

hla.dgoi@gmail.comDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России03122018134677402012019020120192018https://oncohematology.abvpress.ru/ongm/article/view/322

Natural killer (NK) cells are the first population to recover after allogeneic hematopoietic stem cell transplantation. Since the report in 2002 by L. Rugerri et al. showing the effectiveness of NK cell alloreactivity in haploidentical stem cell transplantation, a lot of conflicting studies have appeared about the role of NK alloreactivity in haploidentical and matched unrelated donor transplantations. Current studies demonstrate that the beneficial effects of donor NK alloreactivity are dependent on the transplant protocol – conditioning regimen, graft processing procedure and graft-versus-host disease.

Естественные киллерные (natural killer, NK) клетки являются 1-й популяцией лимфоцитов, которая восстанавливается после аллогенной трансплантации гемопоэтических стволовых клеток (ТГСК). После того как в 2002 г. L. Rugerri и соавт. показали роль NK-аллореактивности при гаплоидентичной ТГСК, появилось множество противоречивых исследований о NK-аллореактивности при гаплоидентичной и совместимой неродственной ТГСК. Современные представления говорят о влиянии на NK-аллореактивность трансплантационного протокола ‒ вида режима кондиционирования, процессинга трансплантата, а также посттрансплантационной профилактики реакции «трансплантат против хозяина».

killer cell immunoglobulin-like receptorsKIR typingHLA typinghematopoietic stem cell transplantationиммуноглобулиноподобные рецепторы киллерных клетокKIR-типированиеHLA-типированиетрансплантация гемопоэтических стволовых клеток1. Cooley S., Trachtenberg E., Bergemann T.L. et al. Donor with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009;113(3):726–32. DOI: 10.1182/blood-2008-07-171926. PMID: 18945962.Cooley S., Trachtenberg E., Bergemann T.L. et al. Donor with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009;113(3):726–32. DOI: 10.1182/blood-2008-07-171926. PMID: 18945962.2. Spierings E., Kim Y., Hendriks M. et al. Multicenter analyses demonstrate significant clinical effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(8):1244–53. DOI: 10.1016/j.bbmt.2013.06.001. PMID: 23756210.Spierings E., Kim Y., Hendriks M. et al. Multicenter analyses demonstrate significant clinical effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(8):1244–53. DOI: 10.1016/j.bbmt.2013.06.001. PMID: 23756210.3. Rugerri L., Capanni M., Casucci M. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94(1):333–9. PMID: 10381530.Rugerri L., Capanni M., Casucci M. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94(1):333–9. PMID: 10381530.4. The HLA complex in Biology and Medicine: A Resource Book. Eds.: N.K. Mehra, G. Kaur, J. McCluskey et al. New Delhi: Jaypee Brothers Medical Publishers LTD, 2010.The HLA complex in Biology and Medicine: A Resource Book. Eds.: N.K. Mehra, G. Kaur, J. McCluskey et al. New Delhi: Jaypee Brothers Medical Publishers LTD, 2010.5. Ciccone E., Viale O., Pende D. et al. Specific lysis of allogeneic cells after activation of CD3-lymphocytes in mixed lymphocyte culture. J Exp Med 1988;168(6):2403–8. PMID: 2974067.Ciccone E., Viale O., Pende D. et al. Specific lysis of allogeneic cells after activation of CD3-lymphocytes in mixed lymphocyte culture. J Exp Med 1988;168(6):2403–8. PMID: 2974067.6. Moretta A., Bottino C., Pende D. et al. Identification of four subsets of human CD3 – CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172(6):1589–98. PMID: 2147946.Moretta A., Bottino C., Pende D. et al. Identification of four subsets of human CD3 – CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172(6):1589–98. PMID: 2147946.7. Ciccone E., Pende D., Moretta A. et al. Evidence of natural killer (NK) cell repertoire for (Allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992;175(3):709–18. PMID: 1371301.Ciccone E., Pende D., Moretta A. et al. Evidence of natural killer (NK) cell repertoire for (Allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992;175(3):709–18. PMID: 1371301.8. Ciccone E., Pende D., Viale O. et al. Involvement of HLA Class 1 alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones dysplaing a defined specificity. J Exp Med 1992;176(4):963–71. PMID: 1328466.Ciccone E., Pende D., Viale O. et al. Involvement of HLA Class 1 alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones dysplaing a defined specificity. J Exp Med 1992;176(4):963–71. PMID: 1328466.9. Colonna M., Brooks E.G., Falco M. et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993;260(5111):1121–4. PMID: 8493555.Colonna M., Brooks E.G., Falco M. et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993;260(5111):1121–4. PMID: 8493555.10. Cella M., Longo A., Ferrara G.B. et al. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180(4):1235–42. PMID: 7931060.Cella M., Longo A., Ferrara G.B. et al. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994;180(4):1235–42. PMID: 7931060.11. Foley B.A., De Santis D.D., Van Beelen E. et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008;112(2):435–43. DOI: 10.1182/blood-2008-01-132902. PMID: 18385451.Foley B.A., De Santis D.D., Van Beelen E. et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008;112(2):435–43. DOI: 10.1182/blood-2008-01-132902. PMID: 18385451.12. Ljunggren H.G., Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 1990;11(7):237–44. PMID: 2201309.Ljunggren H.G., Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 1990;11(7):237–44. PMID: 2201309.13. Oevermann L., Michaelis S.U., Mezger M. et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 2014;124(17):2744–7. DOI: 10.1182/blood-2014-03-565069. PMID: 25115891.Oevermann L., Michaelis S.U., Mezger M. et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 2014;124(17):2744–7. DOI: 10.1182/blood-2014-03-565069. PMID: 25115891.14. Uhrberg M., Valiante N.M., Shum B.P. et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7(6):753–63. PMID: 9430221.Uhrberg M., Valiante N.M., Shum B.P. et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7(6):753–63. PMID: 9430221.15. Witt C.S., Dewing C.B., Sayer D.C. et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999;68(11):1784–9. PMID: 10609957.Witt C.S., Dewing C.B., Sayer D.C. et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999;68(11):1784–9. PMID: 10609957.16. Savani B.N., Mielke S., Adams S. et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007;21(10):2145–52. DOI: 10.1038/sj.leu.2404892. PMID: 17673900.Savani B.N., Mielke S., Adams S. et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007;21(10):2145–52. DOI: 10.1038/sj.leu.2404892. PMID: 17673900.17. Stewart C.A., Laugier-Anfossi F., Vely F. et al. Recognition of peptide-MHC class 1 complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102(37):13224–9. DOI: 10.1073/pnas.0503594102. PMID: 16141329.Stewart C.A., Laugier-Anfossi F., Vely F. et al. Recognition of peptide-MHC class 1 complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102(37):13224–9. DOI: 10.1073/pnas.0503594102. PMID: 16141329.18. Chewning J.H., Gudme C.N., Hsu K.C. et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007;179(2):854–68. PMID: 17617576.Chewning J.H., Gudme C.N., Hsu K.C. et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007;179(2):854–68. PMID: 17617576.19. Rugerri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097–100. DOI: 10.1126/science.1068440. PMID: 11896281.Rugerri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097–100. DOI: 10.1126/science.1068440. PMID: 11896281.20. Ghayur T., Seemayer T.A., Kongshavn P.A. et al. Graft-versus-host reactions in the beige mouse: an investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versushost disease. Transplantation 1987;44(2):261–7. PMID: 3307050.Ghayur T., Seemayer T.A., Kongshavn P.A. et al. Graft-versus-host reactions in the beige mouse: an investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versushost disease. Transplantation 1987;44(2):261–7. PMID: 3307050.21. Cooley S., McCullar V., Wangen R. et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005;106(13): 4370–6. DOI: 10.1182/blood-2005-04-1644. PMID: 16131567.Cooley S., McCullar V., Wangen R. et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005;106(13): 4370–6. DOI: 10.1182/blood-2005-04-1644. PMID: 16131567.22. Yabe T., Matsuo K., Hirayasu K. et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-CKIR ligand-mismatched T cellreplete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008;14(1):75–87. DOI: 10.1016/j.bbmt.2007.09.012. PMID: 18158964.Yabe T., Matsuo K., Hirayasu K. et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-CKIR ligand-mismatched T cellreplete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008;14(1):75–87. DOI: 10.1016/j.bbmt.2007.09.012. PMID: 18158964.23. Rhoades J.L., Cibull M.L., Thompson J.S. et al. Role of natural killer cells in the pathogenesis of human acute graftversus-host disease. Transplantation 1993;56(1):113–20. PMID: 8333033.Rhoades J.L., Cibull M.L., Thompson J.S. et al. Role of natural killer cells in the pathogenesis of human acute graftversus-host disease. Transplantation 1993;56(1):113–20. PMID: 8333033.24. Ferrara J.L., Guillen F.J., Dijken P.J. et al. Evidence that large granular lymphocytes of donor origin mediate acute graft-versushost disease. Transplantation 1989;47(1):50–4. PMID: 2643231.Ferrara J.L., Guillen F.J., Dijken P.J. et al. Evidence that large granular lymphocytes of donor origin mediate acute graft-versushost disease. Transplantation 1989;47(1):50–4. PMID: 2643231.25. Shilling H.G., McQueen K.L., Cheng N.W. et al. Reconstitution of NK cell receptor repertoire following HLAmatched hematopoietic stem cell transplantation. Blood 2003;101(9):3730–40. DOI: 10.1182/blood-2002-08-2568. PMID: 12511415.Shilling H.G., McQueen K.L., Cheng N.W. et al. Reconstitution of NK cell receptor repertoire following HLAmatched hematopoietic stem cell transplantation. Blood 2003;101(9):3730–40. DOI: 10.1182/blood-2002-08-2568. PMID: 12511415.26. Pende D., Marcenaro S., Falco M. et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113(13):3119–29. DOI: 10.1182/blood-2008-06-164103. PMID: 18945967.Pende D., Marcenaro S., Falco M. et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113(13):3119–29. DOI: 10.1182/blood-2008-06-164103. PMID: 18945967.27. Vago L., Forno B., Sormani M.P. et al. Temporal, quantitative, and functional characteristics of single KIR positive alloreactive natural killer cell recovery account for impaired graft-versusleukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008;112(8):3488–99. DOI: 10.1182/blood-2007-07-103325. PMID: 18645039.Vago L., Forno B., Sormani M.P. et al. Temporal, quantitative, and functional characteristics of single KIR positive alloreactive natural killer cell recovery account for impaired graft-versusleukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008;112(8):3488–99. DOI: 10.1182/blood-2007-07-103325. PMID: 18645039.28. Rugerri L., Mancusi A., Capanni M. et al. Donor natural killer cell allorecognition of “missing self” in haploidentical hematpoietic stem cell transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433–40. DOI: 10.1182/blood-2006-07-038687. PMID: 17371948.Rugerri L., Mancusi A., Capanni M. et al. Donor natural killer cell allorecognition of “missing self” in haploidentical hematpoietic stem cell transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433–40. DOI: 10.1182/blood-2006-07-038687. PMID: 17371948.29. Locatelli F., Pende D., Maccario R. et al. Haploidentical hematopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009;133(2):171–8. DOI: 10.1016/j.clim.2009.04.009. PMID: 19481979.Locatelli F., Pende D., Maccario R. et al. Haploidentical hematopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009;133(2):171–8. DOI: 10.1016/j.clim.2009.04.009. PMID: 19481979.30. Triplett B., Handgretinger R., Pui C.H., Leung W. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 2006;107(3):1238–9. DOI: 10.1182/blood-2005-07-2809. PMID: 16434496.Triplett B., Handgretinger R., Pui C.H., Leung W. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 2006;107(3):1238–9. DOI: 10.1182/blood-2005-07-2809. PMID: 16434496.31. Leung W., Iyengar R., Turner V. et al. Determinants of antileukemia effect of allogenic NK cells. J Immunol 2004;172(1):644–50. PMID: 14688377.Leung W., Iyengar R., Turner V. et al. Determinants of antileukemia effect of allogenic NK cells. J Immunol 2004;172(1):644–50. PMID: 14688377.32. Bishara A., Santis D.D., Witt C.C. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004;63(3):204–11. DOI: 10.1111/j.0001-2815.2004.00182.x. PMID: 14989709.Bishara A., Santis D.D., Witt C.C. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004;63(3):204–11. DOI: 10.1111/j.0001-2815.2004.00182.x. PMID: 14989709.33. Huang X.J., Zhao X.Y., Liu D.H. et al. Deleterious effect of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemi 2007;21(4):848–51. DOI: 10.1038/sj.leu.2404566. PMID: 17268518.Huang X.J., Zhao X.Y., Liu D.H. et al. Deleterious effect of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemi 2007;21(4):848–51. DOI: 10.1038/sj.leu.2404566. PMID: 17268518.34. Zhao X.Y., Huang K.Y., Liu K.Y. et al. Prognosis after unmanipulated HLAhaploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007;78(4):338–46. DOI: 10.1111/j.1600-0609.2007.00822.x. PMID: 17378893.Zhao X.Y., Huang K.Y., Liu K.Y. et al. Prognosis after unmanipulated HLAhaploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007;78(4):338–46. DOI: 10.1111/j.1600-0609.2007.00822.x. PMID: 17378893.35. Giebel S., Dziaczkowska J., Wojnar J. et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic hematopoietic stem cell transplantation. Ann Transplant 2005;10(2):29–33. PMID: 16218030.Giebel S., Dziaczkowska J., Wojnar J. et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic hematopoietic stem cell transplantation. Ann Transplant 2005;10(2):29–33. PMID: 16218030.36. Muller C., Schernthaner G., Kovarik J. et al. Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. Clin Immunol Immunopathol 1987;44(1):12–9. PMID: 3297437.Muller C., Schernthaner G., Kovarik J. et al. Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. Clin Immunol Immunopathol 1987;44(1):12–9. PMID: 3297437.37. Wang H., Grzywacz B., Sukovich D. et al. The unexpected effect of cyclosporine A on CD56+. Blood 2007;110(5):1530–9. DOI: 10.1182/blood-2006-10-048173. PMID: 17495133.Wang H., Grzywacz B., Sukovich D. et al. The unexpected effect of cyclosporine A on CD56+. Blood 2007;110(5):1530–9. DOI: 10.1182/blood-2006-10-048173. PMID: 17495133.